59
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study

, , , &
Pages 1145-1152 | Published online: 12 Apr 2017

References

  • Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease2017 Report. Available from: htttp://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/Accessed December 19, 2016
  • MiravitllesMVogelmeierCRocheNA review of national guidelines for management of COPD in EuropeEur Respir J20164762563726797035
  • VogelmeierCHedererBGlaabTTiotropium vesus salmeterol for the prevention of exacerbations of COPDN Engl J Med20113641093110321428765
  • DecramerMLChapmanKRDalhROnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med2013152453324461613
  • JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J20124083083622441743
  • FuhrRMagnussenHSaremKEfficacy of aclidinium bromide 400 mg twice daily compared with placebo and tiotropium in patients with moderate to severe COPDChest201214174575221903737
  • BeierJKirstenAMMrózREfficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6 week, randomized, controlled Phased IIIb studyCOPD201310511522
  • JonesPWLeidyNKHareendranALamarcaRChuecosFGarcia GilEThe effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studiesRespir Res20161716127215749
  • BolíbarBFina AvilésFMorrosRSIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic researchMed Clin (Barc)201213861762122444996
  • BarrechegurenMMonteagudoMFerrerJTreatment patterns in COPD patients newly diagnosed in primary care. A population-based studyRespir Med2016111475326758585
  • CorradoARossiAHow far is real life from COPD therapy guidelines? An Italian observational studyRespir Res2012106989997
  • de MiguelDJIzquierdo AlonsoJLMolina ParisJBellon CanoJMRodriguez Gonzalez-MoroJMde LucasPFactors affecting drug prescription in patients with stable COPD: results from a multicenter Spanish study (IDENTEPOC)Arch Bronconeumol200541637015717999
  • MiravitllesMMayordomoCArtésMSánghez-AgudoLNicolauFSegúJLTreatment of chronic obstructive pulmonary disease and its exacerbations in General PracticeRespir Med19999317317910464874
  • MiravitllesMSoler-CataluñaJJCalleMSpanish Guideline for COPD (GesEPOC). Update 2014Arch Bronconeumol201450Suppl 1116
  • TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
  • AnzuetoAMiravitllesMEfficacy of tiotropium in the prevention of exacerbations of COPDTher Adv Respir Dis2009310311119617284
  • RocheNJebrakGCaillaudDReal-life use of long-acting antimuscarinic agents following their approval for COPD treatmentEur Respir J20154526026225359339
  • BrusselleGPriceDGruffydd-JonesKThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInt J COPD20151022072217
  • MonteagudoMRodriguez-BlancoTParcetJVariability in the performing of spirometry and its consequences in the treatment of COPD in primary careArch Bronconeumol2010475226233
  • BourbeauJBartlettSJPatient adherence in COPDThorax20086383183818728206
  • CramerJABradley-KennedyCScaleraATreatment persistent and compliance with medications for chronic obstructive pulmonary diseaseCan respir J2007141252917315055
  • PriceDMiravitllesMPavordIFirst maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysisNPJ Prim Care Respir Med2016261606127808096
  • MiravitllesMAnzuetoAA new two-step algorihm for the treatment of COPDEur Respir J2017492160220028179443
  • MiravitllesMChapmanKChuecosFRiberaAGarcia GilEThe efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptoms status: a pooled analysisInt J COPD20161120412053
  • Soler-CataluñaJJSauledaJValdésLPrevalence and perception of 24-h symptom patterns in patients with stable chronic obstructive pulmonary disease in SpainArch Bronconeumol20165230831526774700
  • ArfèANicotraFCerveriIIncidence, predictors and clinical implications of discontinuing therapy with inhaled long-acting bronchodilators among patients with chronic obstructive pulmonary diseaseCOPD20161354054626934569
  • BlasiFRaddiFMiravitllesMInteractive monitoring service and COPD: is it possible to reduce nonadherence?COPD20151222723225093542
  • IzquierdoJLParederoJMPiedraRRelevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPDInt J Chron Obst Pulm Dis201611289293
  • SanduzziABalboPCandoliPCOPD: adherence to therapyMultidiscip Respir Med201496025485108
  • Koehorst-terKKortSvan der PalenJQuality of life and adherence to inhaled corticosterois and tiotropium in COPD are relatedInt J Chron Obst Pulm Dis20161116791688
  • RocheNReddelHMartinRQuality standards for real-world researchAnn Am Thorac Soc201411S99S10424559028